Payment overview · 2025
General Payments
$60.56
4 reported records · 3 companies
Healthcare provider profile · identity verified
Julia Keeling Brown, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SPRINGFIELD, KY · NPI 1669459434
Verified facts
What the public records show
CMS Open Payments records show Julia Keeling Brown, MD received $60.56 in general payments during 2025 across 4 reported records.
PFIZER INC. accounted for 51.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 416 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $31.01 | 51.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.51 | 25.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.04 | 23.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $60.56 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $31.01 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $31.01 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.51 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 416 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
416 | 57 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 665 | 147 |
| Levothyroxine Sodium | Levothyroxine Sodium | 650 | 117 |
| Atorvastatin Calcium | Atorvastatin Calcium | 540 | 130 |
| Omeprazole | Omeprazole | 494 | 106 |
| Famotidine | Famotidine | 460 | 85 |
| Gabapentin | Gabapentin | 450 | 75 |
| Potassium Chloride | Potassium Chloride | 434 | 80 |
| Eliquis | Apixaban | 416 | 57 |
| Furosemide | Furosemide | 403 | 71 |
| Memantine Hcl | Memantine Hcl | 351 | 52 |
| Carvedilol | Carvedilol | 344 | 69 |
| Donepezil Hcl | Donepezil Hcl | 336 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 305 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 299 | 62 |
| Losartan Potassium | Losartan Potassium | 295 | 53 |
| Montelukast Sodium | Montelukast Sodium | 260 | 55 |
| Lisinopril | Lisinopril | 251 | 66 |
| Metoprolol Tartrate | Metoprolol Tartrate | 242 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 237 | 40 |
| Cephalexin | Cephalexin | 236 | 127 |
| Azithromycin | Azithromycin | 232 | 158 |
| Ezetimibe | Ezetimibe | 223 | 72 |
| Citalopram Hbr | Citalopram Hydrobromide | 218 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 217 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 214 | 47 |
| Diclofenac Sodium | Diclofenac Sodium | 205 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 203 | 44 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 203 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 200 | 87 |
| Sertraline Hcl | Sertraline Hcl | 191 | 25 |
| Methylprednisolone | Methylprednisolone | 190 | 142 |
| Valsartan | Valsartan | 183 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 182 | 38 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 179 | 38 |
| Lorazepam | Lorazepam | 152 | 45 |
| Glipizide | Glipizide | 145 | 32 |
| Trazodone Hcl | Trazodone Hcl | 144 | 24 |
| Tramadol Hcl | Tramadol Hcl | 143 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 142 | 38 |
| Alprazolam | Alprazolam | 137 | 23 |
| Xarelto | Rivaroxaban | 134 | 13 |
| Atenolol | Atenolol | 132 | 25 |
| Baclofen | Baclofen | 129 | 48 |
| Myrbetriq | Mirabegron | 123 | 12 |
| Cefdinir | Cefdinir | 122 | 77 |
| Paroxetine Hcl | Paroxetine Hcl | 122 | 21 |
| Glipizide Er | Glipizide | 106 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 105 | 20 |
| Sucralfate | Sucralfate | 105 | 18 |
| Buspirone Hcl | Buspirone Hcl | 103 | 18 |
| Nystatin | Nystatin | 103 | 46 |
| Allopurinol | Allopurinol | 101 | 19 |
| Latanoprost | Latanoprost | 99 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 98 | 26 |
| Mirtazapine | Mirtazapine | 97 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 96 | 42 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 94 | 24 |
| Meloxicam | Meloxicam | 92 | 26 |
| Ondansetron Hcl | Ondansetron Hcl | 92 | 69 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 91 | 47 |
| Benazepril Hcl | Benazepril Hcl | 90 | 25 |
| Metformin Hcl | Metformin Hcl | 88 | 19 |
| Olanzapine | Olanzapine | 83 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 79 | 22 |
| Simvastatin | Simvastatin | 79 | 21 |
| Diazepam | Diazepam | 77 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 17 |
| Irbesartan | Irbesartan | 75 | 16 |
| Ozempic | Semaglutide | 73 | 17 |
| Spironolactone | Spironolactone | 68 | 19 |
| Pregabalin | Pregabalin | 67 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 61 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 13 |
| Januvia | Sitagliptin Phosphate | 58 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 58 | 33 |
| Doxycycline Hyclate | Doxycycline Hyclate | 56 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 11 |
| Meclizine Hcl | Meclizine Hcl | 55 | 34 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | suppressed |
| Amoxicillin | Amoxicillin | 54 | 35 |
| Linzess | Linaclotide | 54 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 52 | suppressed |
| Primidone | Primidone | 52 | suppressed |
| Synthroid | Levothyroxine Sodium | 50 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 48 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 48 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | 12 |
| Fluconazole | Fluconazole | 48 | 33 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | suppressed |
| Estradiol | Estradiol | 47 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 45 | 12 |
| Digoxin | Digoxin | 43 | suppressed |
| Fentanyl | Fentanyl | 42 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 42 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 40 | suppressed |
| Nitroglycerin | Nitroglycerin | 38 | 27 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 38 | suppressed |
| Lamotrigine | Lamotrigine | 36 | suppressed |
| Acyclovir | Acyclovir | 35 | 14 |
| Colestipol Hcl | Colestipol Hcl | 35 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 20 |
| Terazosin Hcl | Terazosin Hcl | 35 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 34 | suppressed |
| Timolol Maleate | Timolol Maleate | 34 | suppressed |
| Temazepam | Temazepam | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Bumetanide | Bumetanide | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Prednisone | Prednisone | 30 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 29 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Levofloxacin | Levofloxacin | 27 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 19 |
| Brimonidine Tartrate | Brimonidine Tartrate | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 24 | suppressed |
| Mirabegron Er | Mirabegron | 24 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 23 | suppressed |
| Metronidazole | Metronidazole | 23 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 23 | suppressed |
| Clonidine | Clonidine | 22 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 22 | suppressed |
| Brilinta | Ticagrelor | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 21 | 21 |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Eplerenone | Eplerenone | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Nabumetone | Nabumetone | 17 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Ursodiol | Ursodiol | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Protonix | Pantoprazole Sodium | 12 | suppressed |
| Ssd | Silver Sulfadiazine | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 11 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
| Jublia | Efinaconazole | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $60.56 · 4 records | PFIZER INC. | Cologuard Collection Kit, ELIQUIS, NURTEC ODT, TRELEGY ELLIPTA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error